Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

Abstract

Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECTIVE To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced biliary tract cancer. DESIGN, SETTING, AND PARTICIPANTS This open-label, single-arm, phase 2 clinical trial conducted at the University of Texas MD Anderson Cancer Center and the Mayo Clinic in Phoenix, Arizona, enrolled 62 patients with advanced biliary tract cancers between April 14, 2015, and April 24, 2017. INTERVENTIONS Patients initially received gemcitabine, 1000 mg/m 2 , cisplatin, 25 mg/m 2 , and nab-paclitaxel, 125 mg/m 2 , on days 1 and 8 of 21-day cycles. Owing to hematologic adverse events among the first 32 patients enrolled, these starting doses were reduced to 800, 25, and 100 mg/m 2 , respectively, for the remaining 28 patients. MAIN OUTCOMES AND MEASURES The primary trial end point was investigator-assessed progression-free survival in the intention-to-treat population. RESULTS Of 60 patients who started treatment, the mean (SD) age was 58.4 (11.0) years, 38 (63%) had intrahepatic cholangiocarcinoma, 9 (15%) had extrahepatic cholangiocarcinoma, 13 (22%) had gallbladder cancer, 47 (78%) had metastatic disease, and 13 (22%) had locally advanced disease. Median follow-up was 12.2 (95% CI, 9.4-19.4) months, and median progression-free survival was 11.8 (95% CI, 6.0 to 15.6) months. The partial response rate was 45%, and the disease control rate was 84%. Median overall survival was 19.2 months (95% CI, 13.2 months to not estimable). Patients in the safety population (n = 57) received a median of 6 (interquartile range, 3-11) cycles of treatment; 26 patients (46%) remained on their starting dose throughout the trial. Grade 3 or higher adverse events occurred in 58% of patients, and 9 patients (16%) withdrew owing to adverse events. Neutropenia was the most common grade 3 or higher adverse event, occurring in 19 patients (33%) overall. Post hoc analyses showed that treatment efficacy was not significantly associated with starting dose, tumor type, or disease status and that tolerability was improved with reduced-vs high-dose treatment. CONCLUSIONS AND RELEVANCE Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolonged median progression-free survival and overall survival vs those reported for historical controls treated with gemcitabine-cisplatin alone. These findings will be tested in a phase 3 randomized clinical trial.

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies

“…These observations also argue against the "treatment nihilism" often shown in these diseases whereby a significant proportion of patients are never even offered any further treatment or genomic testing. It is important to note that it is not just the targeted therapies that are options [15,16]. Chemotherapy combinations, for example gemcitabine, cisplatin and nab-paclitaxel, in a phase 2 trial resulted in a median overall survival of 19.2 months as opposed to the historic less than 1 year [16].…”

New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma

“…Another unanswered question is whether more intensive treatment is superior to a two-drug' s standard combo. Some interesting trials addressed this issue, such as the aBTCs trial, a phase II trial focused on triplet therapy cisplatin, gemcitabine and nab-paclitaxel [26], as well as the phase III trial of cisplatin, gemcitabine plus S1 [27].…”

Combined treatment for locally advanced cholangiocellular liver cancer - the case report

“…In such cases the current conservative treatment strategies with application of radiotherapy, systemic and regional chemotherapy attract firstly by their relative safety and by increasing effectiveness [6,7,8]. Combination of gemcitabine, cisplatin and nab-paclitaxel allowed to reach a partial answer to therapy in 45% of cases [9]. For some of the previously inoperable patients (12.5-36.4%) liver resection can be performed after induction chemoradiotherapy is applied and then, in R0-surgery cases it can help to achieve survival results comparable to the ones for primary resectable cases [5,10].…”